Blepharitis - Pipeline Review, H1 2015

Published: Jan, 2015 | Pages: 46 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Blepharitis - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Blepharitis - Pipeline Review, H1 2015', provides an overview of the Blepharitis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Blepharitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Blepharitis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Blepharitis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Blepharitis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Blepharitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Blepharitis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Blepharitis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Blepharitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Blepharitis Overview 6
Therapeutics Development 7
Pipeline Products for Blepharitis - Overview 7
Pipeline Products for Blepharitis - Comparative Analysis 8
Blepharitis - Therapeutics under Development by Companies 9
Blepharitis - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Unknown Stage Products 13
Blepharitis - Products under Development by Companies 14
Blepharitis - Companies Involved in Therapeutics Development 15
Foamix Pharmaceuticals Ltd. 15
InSite Vision Incorporated 16
Laboratoires Thea S.A. 17
Novaliq GmbH 18
Blepharitis - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Combination Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 28
(azithromycin + dexamethasone) - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
azithromycin - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
dexamethasone - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
ISV-405 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
minocycline Gel - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Nov-137 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Blepharitis - Recent Pipeline Updates 35
Blepharitis - Dormant Projects 37
Blepharitis - Product Development Milestones 38
Featured News & Press Releases 38
Jul 08, 2014: InSite Vision Plans to Submit New Drug Application to FDA for DexaSite� for the Treatment of Blepharitis in Adults 38
Jul 23, 2013: InSite Vision Announces Top-line Results from the DOUBle Phase 3 Clinical Study for the Treatment of Moderate-to-Severe Blepharitis 39
Mar 25, 2013: InSite Vision Completes DOUBle Phase III Clinical Study Of AzaSite Plus And DexaSite For Treatment Of Blepharitis 39
Sep 07, 2012: InSite Vision Fully Enrolls Phase III DOUBle Clinical Study Of AzaSite Plus And DexaSite For Blepharitis 41
May 25, 2011: InSite Vision Receives SPA From FDA For DOUBle Phase III Clinical Trial Of AzaSite Plus And DexaSite 42
Apr 14, 2011: InSite Vision Updates Special Protocol Assessment Submission To FDA For Phase III Trial Of AzaSite Plus And DexaSite 43
Apr 26, 2010: Foamix is granted a fourth U.S. patent for OilGel, directed to pharmaceutical compositions and their dermatological, gynecological and ophthalmic applications 44
Appendix 45
Methodology 45
Coverage 45
Secondary Research 45
Primary Research 45
Expert Panel Validation 45
Contact Us 46
Disclaimer 46

List of Tables
Number of Products under Development for Blepharitis, H1 2015 7
Number of Products under Development for Blepharitis - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Late Stage Development, H1 2015 10
Comparative Analysis by Clinical Stage Development, H1 2015 11
Comparative Analysis by Early Stage Development, H1 2015 12
Comparative Analysis by Unknown Stage Development, H1 2015 13
Products under Development by Companies, H1 2015 14
Blepharitis - Pipeline by Foamix Pharmaceuticals Ltd., H1 2015 15
Blepharitis - Pipeline by InSite Vision Incorporated, H1 2015 16
Blepharitis - Pipeline by Laboratoires Thea S.A., H1 2015 17
Blepharitis - Pipeline by Novaliq GmbH, H1 2015 18
Assessment by Monotherapy Products, H1 2015 19
Assessment by Combination Products, H1 2015 20
Number of Products by Stage and Target, H1 2015 22
Number of Products by Stage and Mechanism of Action, H1 2015 24
Number of Products by Stage and Route of Administration, H1 2015 26
Number of Products by Stage and Molecule Type, H1 2015 27
Blepharitis Therapeutics - Recent Pipeline Updates, H1 2015 35
Blepharitis - Dormant Projects, H1 2015 37